2022 World Conference on Lung Cancer (ePosters)-EP08.02-040. Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event

Pdf Summary

Dacomitinib is a second-generation oral irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is used to treat metastatic non-small lung cancer patients with EGFR mutations. The common side effects of dacomitinib include diarrhea and dermatological toxicities, but severe neutropenia or febrile neutropenia had not been reported before. However, a case study from Tata Medical Center in India presented the case of a 68-year-old male patient with EGFR mutated metastatic lung cancer who developed febrile neutropenia after starting dacomitinib. The patient presented to the emergency room with high-grade fever and chills, and laboratory tests revealed grade 4 neutropenia. There was no evidence of infection and the fever subsided after antibiotic treatment. The patient's neutrophil counts recovered after stopping dacomitinib and receiving granulocyte colony-stimulating factor support. This is the first reported case of dacomitinib-induced febrile neutropenia in a patient with metastatic non-small lung cancer. The study suggests that clinicians should be aware of this adverse event and consider dose interruption followed by dose reduction in cases of severe neutropenia. In this case, the patient was able to resume dacomitinib at a lower dose without experiencing further neutropenia or severe adverse events. After six months of treatment, the patient had a complete response to dacomitinib. There was no other explanation for the febrile neutropenia, which resolved with drug discontinuation and did not recur after resuming at a lower dose.

Asset Subtitle

Debapriya Mondal

Meta Tag

Speaker Debapriya Mondal

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Dacomitinib

EGFR mutations

febrile neutropenia

metastatic lung cancer

adverse event

neutropenia

case study

dose interruption

lower dose

complete response